OmniAb 경영진
경영진 기준 점검 2/4
OmniAb CEO는 Matt Foehr, Nov2022 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $3.81M, 16.3% 급여 및 83.7% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $11.71M 가치에 해당하는 회사 주식의 3.05% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.4 년과 3.5 년입니다.
핵심 정보
Matt Foehr
최고경영자
US$3.8m
총 보수
| CEO 급여 비율 | 16.29% |
| CEO 재임 기간 | 3.5yrs |
| CEO 지분 보유율 | 3.0% |
| 경영진 평균 재임 기간 | 3.4yrs |
| 이사회 평균 재임 기간 | 3.5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 15
OABI: 2026 Revenue Guidance And Margin Outlook Will Drive Long Term Upside
Analysts have updated their price target on OmniAb, maintaining their fair value estimate at $7.33 while refining assumptions for the discount rate, revenue growth, profit margins, and future P/E to reflect revised expectations for the business. What's in the News OmniAb issued earnings guidance for 2026, setting an expected revenue range of US$25 million to US$30 million.내러티브 업데이트 • Apr 27
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.내러티브 업데이트 • Apr 08
OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).내러티브 업데이트 • Mar 25
OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.내러티브 업데이트 • Mar 08
OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.내러티브 업데이트 • Feb 21
OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.내러티브 업데이트 • Feb 06
OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.내러티브 업데이트 • Jan 22
OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.내러티브 업데이트 • Jan 08
OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).내러티브 업데이트 • Dec 16
OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.내러티브 업데이트 • Dec 02
OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.내러티브 업데이트 • Nov 18
OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.분석 기사 • Oct 10
OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...분석 기사 • Aug 09
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
NasdaqGM:OABI 1 Year Share Price vs Fair Value Explore OmniAb's Fair Values from the Community and select yours...분석 기사 • Jul 09
Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
OmniAb, Inc. ( NASDAQ:OABI ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Seeking Alpha • May 12
OmniAb: Too Much Risk, Not Enough Reward
Summary OmniAb's innovative business model relies on licensing transgenic animals for drug discovery, but financial success hinges on partner drug approvals, which have been slow. Nearly three quarters of the late-stage pipeline's value is concentrated in just a single drug, IMVT-1402. OmniAb faces a cash burn issue, with operating expenses likely to outpace royalties for years before late-stage candidates meaningfully contribute. The FDA's shift away from animal trials threatens OmniAb's core business model, making the stock expensive and risky; I rate it a Sell. Read the full article on Seeking Alpha분석 기사 • May 11
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
It's shaping up to be a tough period for OmniAb, Inc. ( NASDAQ:OABI ), which a week ago released some disappointing...분석 기사 • Apr 20
OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, OmniAb, Inc. ( NASDAQ:OABI ) shares are down a considerable 29% in the last...
새로운 내러티브 • Mar 29
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.분석 기사 • Nov 15
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...분석 기사 • Sep 14
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Jul 15
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Key Insights OmniAb's estimated fair value is US$7.87 based on 2 Stage Free Cash Flow to Equity Current share price of...분석 기사 • May 12
The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
OmniAb, Inc. ( NASDAQ:OABI ) just released its latest quarterly report and things are not looking great. It was not a...분석 기사 • Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Today is shaping up negative for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a substantial...분석 기사 • Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...분석 기사 • Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Key Insights The projected fair value for OmniAb is US$8.52 based on 2 Stage Free Cash Flow to Equity OmniAb's US$6.22...분석 기사 • Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 7.6x may look like a poor investment opportunity when...분석 기사 • Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...분석 기사 • May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on OmniAb, Inc. ( NASDAQ:OABI ) - they aren't optimistic, having just made a...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$54m |
| Dec 31 2025 | US$4m | US$621k | -US$65m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$64m |
| Mar 31 2025 | n/a | n/a | -US$61m |
| Dec 31 2024 | US$4m | US$594k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$62m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$3m | US$564k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$7m | US$542k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$5m | US$519k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$3m | US$504k | -US$18m |
보상 대 시장: Matt의 총 보수(USD3.81M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.64M)보다 높습니다.
보상과 수익: Matt의 보상은 회사가 적자임에도 증가했습니다.
CEO
Matt Foehr (52 yo)
3.5yrs
재임 기간
US$3,811,740
보수
Mr. Matthew W. Foehr, also known as Matt, has been the President, Chief Executive Officer and Director of OmniAb, Inc. since November 1, 2022. Mr. Foehr has been the Chief Executive Officer and President a...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 3.5yrs | US$3.81m | 3.05% $ 11.7m | |
| Executive VP of Finance & CFO | 3.5yrs | US$1.61m | 0.18% $ 692.9k | |
| Chief Legal Officer & Secretary | 3.5yrs | US$1.62m | 0.28% $ 1.1m | |
| Senior Vice President of People & Talent | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Antibody Discovery | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Antibody Technologies | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Exploratory Research | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Discovery Systems | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Business Development & Strategy | no data | 데이터 없음 | 데이터 없음 |
3.4yrs
평균 재임 기간
56yo
평균 나이
경험이 풍부한 관리: OABI의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 3.5yrs | US$3.81m | 3.05% $ 11.7m | |
| Chairman | 3.5yrs | US$150.69k | 2.03% $ 7.8m | |
| Independent Director | 3.5yrs | US$148.19k | 0.064% $ 247.3k | |
| Independent Director | 2.5yrs | US$151.59k | 0.049% $ 189.9k | |
| Independent Director | 1.1yrs | US$253.82k | 0.0092% $ 35.3k | |
| Independent Director | 1.1yrs | US$254.95k | 0.0092% $ 35.3k | |
| Independent Director | 3.5yrs | US$148.19k | 0.11% $ 408.6k |
3.5yrs
평균 재임 기간
55yo
평균 나이
경험이 풍부한 이사회: OABI의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/25 11:54 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
OmniAb, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |